TKTX Transkaryotic Therapies (MM)

TKT to Present at Wachovia Biotechnology Conference CAMBRIDGE, Mass., Dec. 9 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that the company will present at Wachovia Capital Markets' Ten for '05 Biotechnology Conference being held at the Ritz Carlton, Central Park in New York on December 16, 2004. The conference will feature ten companies expected to report pivotal clinical trial results in 2005. David D. Pendergast, Ph.D., Chief Operating Officer of TKT, will present an overview of the company's AIM study (Assessment of I2S in MPS II) at 9:30 a.m. Eastern Standard Time. The AIM study is a pivotal trial evaluating iduronate-2-sulfatase (I2S), TKT's investigational enzyme replacement therapy being development for the treatment of Hunter syndrome. TKT expects top-line results from the AIM study in June 2005, and, if positive, the company expects to submit applications for marketing approval in both the United States and Europe in the second half of 2005. A live audio webcast of this presentation will be available at http://www.tktx.com/ on TKT's Investor Information website under the Events category. A replay will be available for approximately 30 days after the webcast. About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and South America. Additional information about TKT is available on the company's website at http://www.tktx.com/. Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA. For More Information Contact: Daniella M. Lutz Corporate Communications Manager (617) 349-0205 http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies, Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager of Transkaryotic Therapies, Inc., +1-617-349-0205 Web site: http://www.tktx.com/ Company News On-Call: http://www.prnewswire.com/comp/120657.html

Copyright